4563.T WACC - Weighted Average Cost of Capital
The WACC of AnGes Inc (4563.T) is 5.9%.
| Range | Selected | |
| Cost of equity | 5.0% - 6.9% | 5.95% |
| Tax rate | 0.3% - 0.4% | 0.35% |
| Cost of debt | 5.0% - 5.0% | 5% |
| WACC | 5.0% - 6.9% | 5.9% |
| Category | Low | High |
| Long-term bond rate | 1.4% | 1.9% |
| Equity market risk premium | 6.1% | 7.1% |
| Adjusted beta | 0.59 | 0.63 |
| Additional risk adjustments | 0.0% | 0.5% |
| Cost of equity | 5.0% | 6.9% |
| Tax rate | 0.3% | 0.4% |
| Debt/Equity ratio | 0.01 | 0.01 |
| Cost of debt | 5.0% | 5.0% |
| After-tax WACC | 5.0% | 6.9% |
| Selected WACC | 5.9% | |
| Debt/Equity | Unlevered | |||
| Peers | Company Name | ratio | Beta | beta |
| 4563.T | AnGes Inc | 0.01 | 0.32 | 0.31 |
| 2160.T | GNI Group Ltd | 0.05 | 1.71 | 1.63 |
| 2342.T | Trans Genic Inc | 0.78 | 0.65 | 0.37 |
| 4564.T | OncoTherapy Science Inc | 0.01 | 0.45 | 0.45 |
| 4576.T | D.Western Therapeutics Institute Inc | 0.15 | -0.09 | -0.08 |
| 4588.T | Oncolys Biopharma Inc | 0.02 | 1.7 | 1.67 |
| 4592.T | SanBio Co Ltd | 0 | 0.44 | 0.44 |
| 4593.T | Healios KK | 0.16 | 1.47 | 1.26 |
| 6978.HK | Immunotech Biopharm Ltd | 0.08 | 0.43 | 0.4 |
| 6998.HK | JHBP CY Holdings Ltd | 0 | 0.16 | 0.16 |
| Low | High | |
| Unlevered beta | 0.39 | 0.44 |
| Relevered beta | 0.39 | 0.45 |
| Adjusted relevered beta | 0.59 | 0.63 |
4563.T's CAPM model and how its cost of Equity is calculated
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for 4563.T:
cost_of_equity (5.95%) = risk_free_rate (1.65%) + equity_risk_premium (6.60%) * adjusted_beta (0.59) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.